Report Type : Therapy Reports

Report Category : Cardiovascular

Report Subcategory : Pulmonary Arterial Hypertension

Price : 1099.00

Date : February 2023

Pulmonary Arterial Hypertension : Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Top 50 Key Players:

1. Johnson & Johnson
2. F. Hoffmann-La Roche Ltd
3. Bayer AG
4. Novartis AG
5. Merck & Co Inc
6. GlaxoSmithKline Plc
7. Bristol-Myers Squibb Co
8. Gilead Sciences Inc
9. Eli Lilly and Co
10. Boehringer Ingelheim International GmbH
11. Biogen Inc
12. Chiesi Farmaceutici SpA
13. United Therapeutics Corp
14. Mochida Pharmaceutical Co Ltd
15. Handok Inc
16. Lee's Pharmaceutical Holdings Ltd
17. Minapharm Pharmaceuticals & Chemical Industries
18. Insys Therapeutics Inc
19. Acceleron Pharma Inc
20. Correvio Pharma Corp
21. Reata Pharmaceuticals Inc
22. Cipher Pharmaceuticals Inc
23. C4X Discovery Holdings Plc
24. Mezzion Pharma Co Ltd
25. AVEO Oncology Inc
26. Anterogen Co Ltd
27. SteadyMed Ltd
28. PhaseBio Pharmaceuticals Inc
29. Pluristem Therapeutics Inc
30. Actelion Pharmaceuticals Ltd
31. Janssen Global Services LLC
32. APT Therapeutics Inc
33. Northern Therapeutics Inc
34. AVEO Pharmaceuticals Inc
35. Aqualung Therapeutics Corp
36. Gmax Biopharm Ltd
37. Galectin Therapeutics Inc
38. GenThera Inc
39. Excubio Pharmaceuticals Inc
40. Morphogen-IX Ltd
41. Abivax SA
42. Reviva Pharmaceuticals Inc
43. Complexa Inc
44. Aerogen Ltd
45. Government Japan
46. Gossamer Bio Inc
47. Roivant Sciences Ltd
48. Shanghai Institute of Materia Medica Chinese Academy of Sciences
49. Sandberg Development AB
50. Respira Therapeutics Inc